Methods and systems for predicting bleeding risk and dose of plasminogen activator

A system for estimating the clinical responsiveness of a patient to administration of a plasminogen activating agent to treat a thrombosis, comprising:

• at least one biomarker measurement system for determining a concentration of α2-antiplasmin in a blood sample of the patient, a concentration of activated fibrinolysis inhibitor (“TAFI”) in the blood sample, and a concentration of plasminogen activator Inhibitor 1 (“PAI-1”) in the blood sample;
• a computing device in communication with the at least one biomarker measurement system including a processor and a memory including instructions which when executed by the processor cause the computing device to compute a clot lysis time (“CLT”) based on the concentrations of α2-antiplasmin, TAFI and PAI-1 using the equation CLT=−2,813.6+31.1*α2-antiplasmin (percent activity)+31.1*TAFI (percent activity)+1.49 PAI-1 (ug/L), and to compare the computed CLT to a first predetermined cutoff time;
• and
• a user interface configured to provide a user of the computing device information that the patient is at increased risk of hemorrhage when the computed CLT is less than a first predetermined cutoff time.